Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression

Cancer Immunology, Immunotherapy

Volumn 64, Issue 4, 2015, Pages 493-505

  Noguchi, Masanori ^a   Arai, Gaku ^b   Matsumoto, Kazumasa ^c   Naito, Seiji ^d   Moriya, Fukuko ^a   Suekane, Shigetaka ^a   Komatsu, Nobukazu ^a   Matsueda, Satoko ^a   Sasada, Tetsuro ^a   Yamada, Akira ^a   Kakuma, Tatsuyuki ^a   Itoh, Kyogo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KYUSHU UNIVERSITY   (Japan)

Author keywords

Cancer vaccine; Immunotherapy; Mixed peptide; Phase I; Prostate cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CANCER VACCINE; CREATININE; HLA A ANTIGEN; HLA A11 ANTIGEN; HLA A2 ANTIGEN; HLA A24 ANTIGEN; HLA A26 ANTIGEN; HLA A3 ANTIGEN; HLA A31 ANTIGEN; HLA A33 ANTIGEN; IMMUNOGLOBULIN G; KRM 20; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; HLA ANTIGEN; PEPTIDE FRAGMENT; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BONE PAIN; CASTRATION RESISTANT PROSTATE CANCER; COMPRESSION FRACTURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOTOXIC T LYMPHOCYTE; DEHYDRATION; DOSE RESPONSE; DRUG FEVER; DRUG INDUCED HEADACHE; HEMATURIA; HERPES ZOSTER; HUMAN; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; MALE; MINIMUM IMMUNOLOGICAL EFFECTIVE DOSE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TOOTH PAIN; TREATMENT RESPONSE; BLOOD; BONE NEOPLASMS; CANCER GRADING; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; IMMUNOLOGY; LYMPH NODE METASTASIS; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY;

AGED; ANTIGENS, NEOPLASM; BONE NEOPLASMS; CANCER VACCINES; COHORT STUDIES; CTLA-4 ANTIGEN; FOLLOW-UP STUDIES; HLA ANTIGENS; HUMANS; IMMUNOGLOBULIN G; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PEPTIDE FRAGMENTS; PROGNOSIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; T-LYMPHOCYTES, CYTOTOXIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84925487624     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1660-1     Document Type: Article

References (30)

1. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE (1998) Immunologic and therapeutic evaluation of synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321–327
2. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, Gailani F, Riley L, Conlon K, Pockaj B, Kendra KL, White RL, Gonzalez R, Kuzel TM, Curti B, Leming PD, Whitman ED, Balkissoon J, Reintgen DS, Kaufman H, Marincola FM, Merino MJ, Rosenberg SA, Choyke P, Vena D, Hwu P (2011) gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 364:2119–2127
3. Perez SA, Hofe E, Kallinteris NL, Gritzapis AD, Peoples GE, Papamichail M, Baxevanis C (2010) A new era in anticancer peptide vaccines. Cancer 116:2071–2080
4. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM (2009) The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 15:5323–5337
5. Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K (2010) Overcoming the hurdles of randomized clinical trials of therapeutic cancer vaccine. Eur J Cancer 46:1514–1519
6. Correale P, Walmsley K, Zaremba S, Zhu M, Schlom J, Tsang KY (1998) Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide. J Immunol 161:3186–3194
7. Peshwa MV, Shi JD, Ruegg C, Laus R, van Schooten WC (1998) Induction of prostate tumor-specific CD8+ cytotoxic T-lymphocytes in vitro using antigen-presenting cells pulsed with prostatic acid phosphatase peptide. Prostate 36:129–138
8. Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G (1996) Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate 28:65–69
9. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ (2003) Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9:1200–1210
10. Park SI, McCauley LK (2012) Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells. Endocr Relat Cancer 19:243–254
11. Minami T, Matsueda S, Takedatsu H, Tanaka M, Noguchi M, Uemura H, Itoh K, Harada M (2007) Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles. Cancer Immunol Immunother 56:689–698
12. Gohara R, Imai N, Rikimaru T, Yamada A, Hida N, Ichiki M, Kawamoto M, Matsunaga K, Ashihara J, Yano S, Tamura M, Ohkouchi S, Yamana H, Oizumi K, Itoh K (2002) Phase 1 clinical study of cyclophilin B peptide vaccine for patients with lung cancer. J Immunother 25:439–444
13. Noguchi M, Sasada T, Itoh K (2013) Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine. Cancer Immunol Immunother 62:919–929
14. Wang J, Nemoto E, Dennert G (1996) Regulation of CTL by ecto-nictinamide adenine dinucleotide (NAD) involves ADP-ribosylation of a p56lck-associated protein. J Immunol 156:2819–2827
15. Mizukoshi E, Nakamoto Y, Arai K, Yamashita T, Sakai A, Sakai Y, Kagaya T, Yamashita T, Honda M, Kaneko S (2011) Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma. Hepatology 53:1206–1216
16. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454
17. Komatsu N, Matsueda S, Tashiro K, Ioji T, Shichijo S, Noguchi M, Yamada A, Suekane S, Doi A, Moriya F, Matsuoka K, Kuhara S, Itoh K, Sasada T (2012) Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer 118:3208–3221
18. Noguchi M, Uemura H, Naito S, Akaza H, Yamada A, Itoh K (2011) A phase I study of personalized peptide vaccination using 14 kinds of vaccine in combination with low-dose estramustine in HLA-A24-positive patients with castration-resistant prostate cancer. Prostate 71:470–479
19. Terasaki M, Shibui S, Narita Y, Fujimaki T, Aoki T, Kajiwara K, Sawamura Y, Kurisu K, Mineta T, Yamada A, Itoh K (2011) Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen–A24 with recurrent or progressive glioblastoma multiforme. J Clin Oncol 29:337–344
20. Komatsu N, Shichijo S, Nakagawa M, Itoh K (2004) New multiplexed flow cytometric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Lab Invest 64:535–545
21. Scher HI, Halabi S, Tannoch I, Morris M, Stemberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159
22. Simone R, Tenca C, Fais F, Luciani M, De Rossi G, Pesce G, Bagnasco M, Saverino D (2012) A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression. PLoS One 7:e44654
23. Salgaller ML, Marincola F, Comier JN, Rosenberg SA (1996) Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56:4749–4757
24. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM (1997) Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 3:37–44
25. Aucouturier J, Dupuis L, Ganne V (2001) Adjuvants designed for veterinary and human vaccines. Vaccine 19:2666–2672
26. Anderson MJ, Shafer-Weaver K, Greenberg NM, Hurwitz AA (2007) Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer. J Immunol 178:1268–1276
27. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 331:1565–1570
28. Slingluff CL Jr, Petroni GR, Chianese-Bullock KA, Smolkin ME, Hibbitts S, Murphy C, Johansen N, Grosh WW, Yamshchikov GV, Neese PY, Patterson JW, Fink R, Rehm PK (2007) Immunologic and clinical outcomes of a randomized phase II trial of two multipeptide vaccines for melanoma in the adjuvant setting. Clin Cancer Res 13:6386–6395
29. Chianese-Bullock KA, Irvin WP Jr, Petroni GR, Murphy C, Smolkin M, Olson WC, Coleman E, Boerner SA, Nail CJ, Neese PY, Yuan A, Hogan KT, Slingluff CL Jr (2008) A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer. J Immunother 31:420–430
30. Noguchi M, Mine T, Komatsu N, Suekane S, Moriya F, Matsuoka K, Yutani S, Shichijo S, Yamada A, Toh U, Kawano K, Azuma K, Uemura H, Okuno K, Matsumoto K, Yanagimoto H, Yamanaka R, Oka M, Todo S, Sasada T, Itoh K (2010) Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 10:1266–1279